Direkt zum Inhalt
Merck
  • Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Cancer discovery (2014-11-02)
Geou-Yarh Liou, Heike Döppler, Brian Necela, Brandy Edenfield, Lizhi Zhang, David W Dawson, Peter Storz
ZUSAMMENFASSUNG

Desmoplasia and an inflammatory environment are defining features of pancreatic cancer. Unclear is how pancreatic cells that undergo oncogenic transformation can cross-talk with immune cells and how this contributes to the development of pancreatic lesions. Here, we demonstrate that pancreatic acinar cells expressing mutant KRAS can expedite their transformation to a duct-like phenotype by inducing local inflammation. Specifically, we show that KRAS(G12D) induces the expression of intercellular adhesion molecule-1 (ICAM-1), which serves as chemoattractant for macrophages. Infiltrating macrophages amplify the formation of KRAS(G12D)-caused abnormal pancreatic structures by remodeling the extracellular matrix and providing cytokines such as TNF. Depletion of macrophages or treatment with a neutralizing antibody for ICAM-1 in mice expressing oncogenic Kras under an acinar cell-specific promoter resulted in both a decreased formation of abnormal structures and decreased progression of acinar-to-ductal metaplasia to pancreatic intraepithelial neoplastic lesions. We here show that oncogenic KRAS in pancreatic acinar cells upregulates the expression of ICAM-1 to attract macrophages. Hence, our results reveal a direct cooperative mechanism between oncogenic Kras mutations and the inflammatory environment to drive the initiation of pancreatic cancer.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyaninperchlorat, BioReagent, suitable for fluorescence, ≥98.0% (TLC)
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Gadolinium(III)-chlorid Hexahydrat, 99% (titration)
Sigma-Aldrich
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyaninperchlorat, 97%
Sigma-Aldrich
Gadolinium(III)-chlorid Hexahydrat, 99.999% trace metals basis
USP
Dexamethason, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethason, VETRANAL®, analytical standard
Dexamethason, British Pharmacopoeia (BP) Assay Standard